New platic complexes for anticancer therapy (Q10095): Difference between revisions
Jump to navigation
Jump to search
(Removed claim: financed by (P890): Directorate-General for Regional and Urban Policy (Q8361), Removing unnecessary financed by statement) |
(Changed an Item: Change because item Q214255 was merged with Q4859) |
||
| Property / contained in NUTS | Property / contained in NUTS | ||
Revision as of 15:42, 27 December 2020
Project Q10095 in Czech Republic
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | New platic complexes for anticancer therapy |
Project Q10095 in Czech Republic |
Statements
5,848,500.0 Czech koruna
0 references
15,596,000.0 Czech koruna
0 references
37.5 percent
0 references
15 June 2016
0 references
28 September 2019
0 references
VUAB Pharma a.s.
0 references
50°9'46.91"N, 14°23'2.26"E
0 references
25263
0 references
Předmětem řešení projektu jsou nové platičité komplexy (Pt(IV)komplexy) se zvýšenou reaktivitou ve vnitrobuněčném prostředí vyznačené tím, že obsahují slabě vázané a potenciálně reaktivní ekvatoriální anion-ligandy bází silných konjugovaných kyselin. Výsledkem řešení bude zcela nová skupina Pt(IV)komplexů pro protinádorovou terapii se zvýšenou toxicitou a selektivitou na nádorové buňky, s malou toxicitou na zdravé buňky a s dobrou biologickou dostupností z GIT, umožňující perorální podání. a. (Czech)
0 references
The object of the project is new platic complexes (Pt(IV)complexes) with increased reactivity in the intracellular environment marked by the fact that they contain weakly bound and potentially reactive equatorial anion-ligands bases of strong conjugated acids. The result of the solution will be a completely new group of Pt(IV)complexes for anticancer therapy with increased toxicity and selectivity to tumor cells, with low toxicity to healthy cells and with good bioavailability from GIT, allowing oral administration. a. (English)
22 October 2020
0 references
Identifiers
CZ.01.1.02/0.0/0.0/15_018/0004605
0 references